Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 7Colorectal Neoplasms 6Small Cell Lung Carcinoma 3Stomach Neoplasms 2Solid Tumor Cancer 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Rectal Cancer Patients 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Neoadjuvant Chemotherapy 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Efficacy and Safety 1Carcinoma, Ovarian Epithelial 1Advanced Small Intestine Cancer 1

Interventions

irinotecan sucrosofate 1Oxaliplatin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Small Intestine Cancer × irinotecan sucrosofate × Clear all
NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

The Methodist Hospital Research Institute

Phase 1 Not yet recruiting
22 enrolled
Gastrointestinal

Advanced Small Intestine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡